

COSTEM 2019 Scientific Program

as of June 14, 2019

Thursday, October 24, 2019	
Hall A	
15:30-17:00	<i>Industry-supported Symposium</i>
17:00-17:30	<i>Coffee Break</i>
17:30-18:30	<i>Industry-supported Symposium</i>
18:30	Welcome Reception

Friday, October 25, 2019			
	Hall A		
08:00-09:00	<i>Industry-supported Symposium</i>		
09:00-09:15	Short Break		
09:15-10:45	Plenary Session 1		
09:15-09:25	Welcome note: Nicolaus Kröger , Germany; Arnon Nagler , Israel		
09:25-10:05	Controversy: Are Haploidentical donors – the alternative donors of choice? Moderator: Nicolaus Kröger , Germany		
09:25-09:40	Yes: Leonido Luznik , USA		
09:40-09:55	No: Arnon Nagler , Israel		
09:55-10:05	Discussion		
10:05-10:45	Controversy: Can CAR-T cells replace autologous stem cell transplantation in DLBCL? Moderator: Arnon Nagler , Israel		
10:05-10:20	Yes: Stephen J. Schuster , USA		
10:20-10:35	No: Michael R. Bishop , USA		
10:35-10:45	Discussion		
10:45-11:15	Coffee Break, Poster Viewing and Visit Exhibition		
	Hall A		Hall B
11:15-12:45	Session 2: Acute Lymphoblastic Leukemia		Session 3: Alternative donor
11:15-12:00	Controversy: How to bridge to transplant in relapsed ALL? Moderator: David Marks , UK		Controversy: Can post-transplant cyclophosphamide be used as GVHD prophylaxis as well in HLA-identical sibling as in MUD transplantation? Moderator: Annalisa Ruggeri , France
11:15-11:25	Pro: Blinatumumab: Nicola Gökbuget , Germany		Yes: Andrea Bacigalupo , Italy
11:25-11:35	Pro: Inotuzumab: Matthias Stelljes , Germany		No: Didier Blaise , France
11:35-11:45	Pro: CAR-T cells: Peihua Lu , China		Discussion
11:45-12:00	Discussion		

12:00-12:45	Controversy: How to cure Ph+ ALL in adults Moderator: Dieter Hoelzer , Germany 12:00-12:10 By allogeneic SCT: David Marks , UK 12:10-12:20 By chemotherapy plus TKI: Renato Bassan , Italy 12:20-12:30 By CAR-T cells: Peter Bader , Germany 12:30-12:45 Discussion	12:00-12:45	Controversy: Can ATG overcome negative outcome of mismatched unrelated donor? Moderator: Andrea Bacigalupo , Italy 12:00-12:15 Yes: Jürgen Finke , Germany 12:15-12:30 No: Robert J. Soiffer , USA 12:30-12:45 Discussion
12:45-13:15	Lunch box pick-up, Poster Viewing and Visit Exhibition		
13:15-14:15	<i>Industry-supported Lunch Symposium – Hall A</i>		
14:15-14:30	Short Break		
	Hall A		Hall B
14:30-16:00	Session 4: Acute Myeloid Leukemia	14:30-16:00	Session 5: Cord blood transplantation
14:30-15:15	Controversy: Myeloablative conditioning regimen should be preferred in all fit AML patients Moderator: Charles Craddock , UK 14:30-14:45 Yes: Bart Lee Scott , USA 14:45-15:00 No: Avichai Shimoni , Israel 15:00-15:15 Discussion	14:30-15:15	Controversy: Is double cord blood transplantation out? Moderator: Annalisa Ruggeri , France 14:30-14:45 Yes: <i>TBA</i> 14:45-15:00 No: Vanderson Rocha , France 15:00-15:15 Discussion
15:15-16:00	Controversy: Is MRD monitoring prior to allograft standard in AML? Moderator: Alessandro Rambaldi , Italy 15:15-15:30 Yes: Michael Heuser , Germany 15:30-15:45 No: Jan Cornelissen , Netherlands 15:45-16:00 Discussion	15:15-16:00	Controversy: Is endothelial protection effective for GVHD, VOD, and TMA? Moderator: Vanderson Rocha , France 15:15-15:30 Yes: Olaf Penack , Germany 15:30-15:45 No: Mohamad Mohty , France 15:45-16:00 Discussion
16:00-16:30	Coffee Break, Poster Viewing and Visit Exhibition		
16:30-17:30	<i>Industry-supported Symposium – Hall A</i>		
17:30-17:45	Short Break		
	Hall A		Hall B
17:45-19:15	Session 6: MDS	17:45-19:15	Session 7: Haplo-identical donor issues
17:45-18:30	Controversy: How to prepare MDS-EB prior to transplantation Moderator: Wael Saber , USA 17:45-17:55 By hypomethylating agents: Marie Robin , France 17:55-18:05 By sequential chemotherapy: Charles Craddock , UK 18:05-18:15 By no intervention: Ibrahim Yakoub-Agha , France 18:15-18:30 Discussion	17:45-18:30	Controversy: Is bone marrow the preferred stem cell source in haplo-SCT setting post cyclophosphamide? Moderator: Jan Cornelissen , Netherlands 17:45-18:00 Yes: Stefan Ciurea , USA 18:00-18:15 No: Annalisa Ruggeri , France 18:15-18:30 Discussion
18:30-19:15	Controversy: Should MDS patients with complex karyotype and p53 mutation receive an allograft?	18:30-19:15	Controversy: What is the optimal GVHD prophylaxis in T-cell repleted haploidentical transplantation?

18:30-18:45	Moderator: Avichai Shimoni , Israel	18:30-18:45	Moderator: Stefan Ciurea , USA
18:45-19:00	Yes: Wael Saber , USA	18:45-19:00	ATG: <i>TBA</i>
19:00-19:15	No: Alessandro Rambaldi , Italy	19:00-19:15	Post Cy: <i>TBA</i>
	Discussion		Discussion

Saturday, October 26, 2019

	Hall A		Hall B
08:00-09:30	Session 8: Aplastic Anemia	08:00-09:30	Session 9: Graft-versus-Host Disease
08:00-08:45	Controversy: Is upfront MUD justified for SAA in 2019? Moderator: Régis Peffault de Latour , France	08:00-08:45	Controversy: Is ruxolitinib the new standard for steroid refractory acute and chronic GVHD? Moderator: Hildegard Greinix , Austria
08:00-08:15	Yes: Carlo Dufour , Italy	08:00-08:15	Yes: Robert Zeiser , Germany
08:15-08:30	No: Antonio Risitano , Italy	08:15-08:30	No: Steven Pavletic , USA
08:30-08:45	Discussion	08:30-08:45	Discussion
08:45-09:30	Controversy: Is haplo better than cord as alternative donor source in SAA? Moderator: Carlo Dufour , Italy	08:45-09:30	Controversy: Is ATG standard GVHD prophylaxis after HLA-identical sibling transplantation? Moderator: Steven Pavletic , USA
08:45-09:00	Yes: Rainer Storb , USA	08:45-09:00	Yes: Francesca Bonifazi , Italy
09:30-09:15	No: Régis Peffault de Latour , France	09:30-09:15	No: Hildegard Greinix , Austria
09:15-09:30	Discussion	09:15-09:30	Discussion
09:30-10:00	Coffee Break, Poster Viewing and Visit Exhibition		
10:00-11:00	<i>Industry-supported Symposium – Hall A</i>		
11:00-11:15	Short Break		
	Hall A		Hall B
11:15-12:45	Session 10: Multiple Myeloma	11:15-12:45	Session 11: Complications
11:15-12:00	Controversy: Is CAR-T cell therapy becoming the new standard for relapsed MM? Moderator: Michele Cavo , Italy	11:15-12:00	Controversy: How can microbiome be better targeted? Moderator: Robert Zeiser , Germany
11:15-11:30	Yes: Hermann Einsele , Germany	11:15-11:30	By fecal transplantation: Francis Ayuk , Germany
11:30-11:45	No: Philippe Moreau , France	11:30-11:45	By antibiotic: Ernst Holler , Germany
11:45-12:00	Discussion	11:45-12:00	Discussion
12:00-12:45	Controversy: Is tandem autologous SCT out for newly diagnosed MM? Moderator: Philippe Moreau , France	12:00-12:45	Controversy: Can third party CMV-specific T-cells replace drug therapy? Moderator: Jan Styczynski , Poland
12:00-12:15	Yes: Sergio A. Giralt , USA	12:00-12:15	Yes: Catherine M. Bollard , USA
12:15-12:30	No: Michele Cavo , Italy	12:15-12:30	No: Per Ljungman , Sweden
		12:30-12:45	Discussion

12:30-12:45	Discussion		
12:15-13:15	Lunch box pick-up, Poster Viewing and Visit Exhibition		
13:15-14:15	<i>Industry-supported Lunch Symposium – Hall A</i>		
14:15-14:30	Short Break		
	Hall A		Hall B
14:30-16:00	Session 12: NHL and Hodgkin's disease	14:30-16:00	Session 13: Relapse prevention
14:30-15:15	Controversy: Can CAR-T cells replace allo SCT in RR DLBCL? Moderator: Anna Sureda , Spain	14:30-15:15	Controversy: Are hypomethylating agents useful to prevent relapse in AML and MDS? Moderator: Ibrahim Yakoub-Agha , France
14:30-14:45	Yes: Ulrich Dührsen , Germany	14:30-14:45	Yes: Marcos de Lima , USA
14:45-15:00	No: Bertram Glass , Germany	14:45-15:00	No: Jakob Passweg , Switzerland
15:00-15:15	Discussion	15:00-15:15	Discussion
15:15-16:00	Controversy: Is a haploidentical donor the donor of choice in relapsed Hodgkin's disease? Moderator: Michael R. Bishop , USA	15:15-16:00	Controversy: Are suicide modified DLIs better than naïve DLIs to prevent relapse? Moderator: Jakob Passweg , Switzerland
15:15-15:30	Yes: Anna Sureda , Spain	15:15-15:30	Yes: Fabio Ciceri , Italy
15:30-15:45	No: Stephen Robinson , UK	15:30-15:45	No: Hans-Jochem Kolb , Germany
15:45-16:00	Discussion	15:45-16:00	Discussion
16:00-16:30	Coffee Break, Poster Viewing and Visit Exhibition		
16:30-17:30	<i>Industry-supported Symposium – Hall A</i>		
17:30-17:45	Short Break		
	Hall A		Hall B
17:45-19:15	Session 14: Autoimmune disease and MPN	17:45-19:15	Session 15: Myeloma (II) / NHL
17:45-18:30	Controversy: Is autologous SCT for R/R MS becoming a standard therapy? Moderator: Tobias Alexander , Germany	17:45-18:30	Controversy: Should maintenance therapy after autograft be limited? Moderator: Sergio A. Giralt , USA
17:45-18:00	Yes: John Snowden , UK	17:45-18:00	Yes: Hartmut Goldschmidt , Germany
18:00-18:15	No: TBA	18:00-18:15	No: Philip L. McCarthy , USA
18:15-18:30	Discussion	18:15-18:30	Discussion
18:30-19:15	Controversy: Can CAR-T cell response be predicted? Moderator: TBA	18:30-19:15	Controversy: Is autologous or allogeneic SCT the standard for peripheral T-cell lymphoma? Moderator: Stephen Robinson , UK
18:30-18:45	Yes, by biomarker: He Huang , China	18:30-18:45	Pro auto: Francesco D'Amore , Denmark
18:45-19:00	Yes, by microbiome: Marcel van den Brink , USA	18:45-19:00	Pro allo: Norbert Schmitz , Germany
19:00-19:15	Discussion	19:00-19:15	Discussion
19:15-20:15	COSTEM Poster Walk and Awards		

Sunday, October 27, 2019

Hall A

08:30-10:00	Session 16: NK-cell therapy
08:30-09:15	Controversy: Are NK-CAR-cells the future of NK-cell therapy? Moderator: Daniel Weisdorf , USA
08:30-08:45	Yes: Katy Rezvani , USA
08:45-09:00	No: Jeffrey Miller , USA
09:00-09:15	Discussion
09:15-10:00	Controversy: Is KIR-typing relevant for donor selection? Moderator: Jeffrey Miller , USA
09:15-09:30	Yes: Daniel Weisdorf , USA
09:30-09:45	No: Carlheinz Müller , Germany
09:45-10:00	Discussion
10:00-10:30	Coffee Break
10:30-12:00	Session 17: Inborn errors
10:30-11:15	Controversy: Is haplo SCT the best curative option for sickle cell disease? Moderator: Arjan Lankester , Netherlands
10:30-10:45	Yes: Selim Corbacioglu , Germany
10:45-11:00	No: <i>TBA</i>
11:00-11:15	Discussion
11:15-12:00	Controversy: Best curative option for thalassemia in 2019? Moderator: Selim Corbacioglu , Germany
11:15-11:30	Gene therapy: Sarah Markt , Italy
11:30-11:45	Allogeneic SCT: Arjan Lankester , Netherlands
11:45-12:00	Discussion
12:00	Farewell Nicolaus Kröger , Germany; Arnon Nagler , Israel